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ABSTRACT 
Objective: Carbapenem resistant Acinetobacter baumannii (CR-Ab) has emerged as a major nosocomial pathogen, but optimal treatment regimens 
are unknown. Our objectives were to determine the epidemiology and outcome of CR-Ab infections at a tertiary care hospital. 
Methods: CR-Ab isolates were collected from January to April 2013. MICs were determined and isolates were subjected to screening for 
carbapenemase production by Modified Hodge test (MHT), metallo-β-lactamase (MBLs) by EDTA disk synergy test and AmpC β-lactamase by AmpC 
disk test. 15 isolates were subjected to PCR for detection of resistant genes, blaOXA-23, blaVIM and blaNDM
Results: 51 CR-Ab isolates from tracheal aspirate (21), blood (15); tissue/wound/drainage (13) and urine samples (2) were collected. Colistin 
appeared to be the most effective agent with 98% in vitro activity. MHT showed 98% positivity, MBLs production was detected in 94.1% isolates 
and 64.7% were positive for AmpC β-lactamase production. All 15 isolates carried bla
. Treatment outcomes of infections were 
evaluated. 
OXA-23 and blaVIM, of these 3 also carried blaNDM gene. Colistin 
containing combinations were more commonly used (68.3%). Colistin-noncarbapenem combination showed improved clinical response compared 
to colistin-carbapenem combination against Acinetobacter isolates carrying blaOXA-23 and blaVIM
Conclusion: A stringent infection control practice along with antimicrobial stewardship is needed to prevent emergence of Acinetobacter carrying 
multiple carbapenemase genes along with bla
. 
NDM
Keywords: Acinetobacter baumannii, Carbapenem resistance, Carbapenemases, Colistin combination, metallo-β-lactamase, NDM 
. Various colistin combinations are preferentially used to treat CR-Ab infections. Identification of 
antimicrobial combinations with proven in vitro activity that encompass local susceptibility patterns as well as molecular mechanisms of resistance 
is needed to provide better outcome.  
© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
 
INTRODUCTION  
Acinetobacter baumannii has emerged as one of the most troublesome 
group of pathogens in the healthcare settings both globally and locally. 
Its remarkable ability to develop or acquire multiple antibiotic resistance 
and tendency to survive for prolonged periods under varied 
environmental conditions, make it a frequent cause of hospital outbreaks 
and an endemic healthcare associated pathogen [1]. 
For many years, the carbapenem class has been considered as the 
drug of choice to treat serious Acinetobacter infections. With the 
rapid escalating prevalence of carbapenem resistant Acinetobacter 
baumannii (CR-Ab) isolates in many parts of the world in past few 
years has undermined the reliability of the carbapenem class [2]. It 
significantly limits treatment options to tigecyclin, aminoglycosides, 
colistin and addition of sulbactam. Clinical experience on the value 
of each of these agents is limited [3]. Despite treatment of infections 
by CR-Ab, it has still been associated with poor outcomes [3]. 
Carbapenem resistance is predominantly conferred by 
carbapenemases, such as oxacillinase (OXA)-type enzymes and 
metallo-β-lactamases (MBLs) [1]. Of these, acquired OXA-type 
enzymes, belonging to families OXA-23,-24 and-58, are more 
prevalent [2]. Some are plasmid-mediated, explaining their rapid 
dissemination. MBLs [mostly Imipenemase (IMP) and Verona Italy 
metallo-β-lactamases (VIM) type and, more recently, of New Delhi 
metallo-β-lactamases (NDM) type] have also been found in A. 
baumannii [4]. Non-enzymatic carbapenem resistance mechanisms 
include membrane porin changes and multi-drug efflux pumps [1, 2]. 
MATERIALS AND METHODS 
So this study aims to characterize the CR-Ab isolates at a tertiary 
care center with emphasis on their mechanism of resistance, 
epidemiology and treatment outcome of the infections caused by 
CR-Ab isolates.  It was a prospective observational study 
conducted in a 750 bedded tertiary care hospital in Mumbai from 
January 2013 to April 2013 (4 mo). This study was approved by the 
Institutional Scientific and Ethics Board (ISEB) of the hospital.  
Non-repeat, consecutive, clinically significant CR-Ab isolates obtained 
from clinical specimens received in microbiology laboratory for 
culture studies that exhibited an imipenem minimal inhibitory 
concentration (MIC)>4 µg/ml, according to Clinical and Laboratory 
Standard Institute (CLSI) guidelines, were considered [5]. All samples 
were processed as per standard microbiology protocol.  
Identification and susceptibility testing of clinical isolates were 
performed by standard techniques using the automated broth 
microdilution system (Vitek 2; BioMerieux Ltd). Sensitivity testing 
against meropenem and amikacin was done using Kirby Baur disk 
diffusion method (HIMEDIA, Mumbai, India) as per CLSI guidelines, 
due to the limitation of sensitivity testing card used in Vitek 2 
analyzer. Carbapenem resistance was rechecked by Kirby Baur disk 
diffusion method and interpreted as per CLSI standards [5]. For 
tigecyclin, interpretive criteria approved by the US Food and Drug 
Administration (US-FDA)[6] for Enterobacteriaceae was used for 
Acinetobacter spp. For colistin, break points proposed by European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) [7] 
were used because relevant break points were not available from 
CLSI. MIC of colistin resistant isolates was rechecked by E-test 
method as per manufacturer’s guidelines (BioMerieux Ltd). 
To characterize the carbapenem resistance mechanism phenotypic 
tests like, Modified Hodge’s test (MHT) for carbapenemase 
production, ethylene-diamine-tetra-acetic acid (EDTA) disk synergy 
test for MBLs production and AmpC disk test for AmpC β-lactamase 
production was performed, as described [8]. 
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Due to limited consumables for PCR, 15 strains were selected at 
random and DNA was extracted from these strains by heat boil 
method. The resistant genes blaOXA-23, blaVIM and blaNDM were 
amplified by single target PCR using previously published primers, 
OXA-23, Oxa-23-F 5’-GATCGGATTGGAGAACCAGA-3’/Oxa-23-R 5’-
ATTTCTGACCGCATTTCCAT-3’; VIM, Vim-F 5’-GATGGTGTTTGGTC 
GCATA-3’/Vim-R 5’-CGAATGCGCAGCACCAG-3’; NDM-F 5’-GGTTTG 
GCGATCTGGTTTTC-3’/NDM-R 5’-CGGAATGGC TCATCACGATC-3’ [9-
11]. Amplified products were visualized under UV light on 3% Agarose 
Gel Electrophoresis. In house strains of A. baumannii and Klebsiella 
pneumonia harboring blaOXA-23, blaVIM and blaNDM 
Data, including patient demographics, co-morbid conditions, source 
of infection, and treatment were collected from the electronic 
medical records, laboratory data and medication administration 
records from the date of admission till discharge. Only single 
clinically significant isolate from the patient was included. Outcome 
at the end of treatment was defined as successful (partial or 
complete improvement of signs/symptoms of infection or positive 
microbial response in terms of sterile culture results post or during 
the treatment), and failure (no improvement or deterioration of 
signs/symptoms of infection or negative microbial response in 
terms of persistent positive culture results with the same organism 
3 d after initiation of antibiotic therapy). Final disposition was 
defined as death, discharged during illness or transferred to ward or 
discharged. 
gene, identified by 
PCR and gene sequencing were included as positive controls.  
RESULTS 
A total of 51 clinically significant CR-Ab were isolated from tracheal 
aspirate (21), blood (15), tissue/wound/drainage (13) and urine 
samples (2) during the study period of 4 mo. Susceptibility profile of 
all the isolates is been given in table 1. Kirby Baur disk diffusion 
method confirmed the carbapenem resistance amongst the isolates 
and did not show any discrepancy in results of susceptibility for 
imipenem. One of the isolate was found to be resistant to colistin 
with an MIC of 4 µg/ml and it was reconfirmed by E strip method. 
This isolate was termed as pandrug resistant (PDR) as it was found 
to be resistant to all other group of drugs tested along with colistin 
[12]. MHT detected carbapenemase production in 50/51 (98%) 
isolates, whereas EDTA-disk synergy test detected MBLs production 
in 48/51 (94.1%) isolates. AmpC β-lactamase was found in 33 
(64.7%) isolates. All 15 isolates considered for PCR analysis were 
found to be carrying blaOXA-23 and blaVIM genes, whereas three of 
these also carried blaNDM 
 
gene. 
Table 1: Susceptibility profile of 51 isolates of Acinetobacter baumannii to various antimicrobials 
Acinetobacter baumannii 
Antimicrobial agent MIC range µg/ml MIC50 MICµg/ml 90 % Sensitivity µg/ml 
Imipenem* 4-16 16 16 0 
Meropenem* ND - - 0 
Amikacin* ND - - 0 
Tobramycin* 1-16 16 16 22 
Gentamycin* 1-16 16 16 8 
Colistin** 0.5-4 0.5 0.5 98 
Tigecyclin*** 0.5-8 2 4 57 
Ciprofloxacin* 4 4 4 0 
Ampicillin sulbactam* 4-32 32 32 6 
Cefoperazone sulbactam* 16-64 64 64 10 
Cotrimoxazole* 20-320 320 320 8 
Note: MIC50, MIC (µg/ml) required to inhibit the growth of 50% isolates of this study, MIC90
 
, MIC (µg/ml) required to inhibit 90% isolates of this 
study, MICs (µg/ml) were determined by broth dilution method, *MICs were interpreted in accordance with the CLSI, **MICs were interpreted in 
accordance with EUCAST, ***MICs were interpreted in accordance with US-FDA, ND-Not done 
Medical records of 51 patients were reviewed. Table 2 describes the 
demographic and clinical features, including co-morbidity, of the 
study cohort (51 patients). Except one neonate, all patients had 
received other antimicrobial agents prior to acquiring infection by 
CR-Ab. Specifically, 78.4% of patients received β-lactam/β-lactamase 
inhibitor (BL/BLI, β-lactamase inhibitor co-formulated with β-
lactam antibiotic) antibiotics, 47.1% of patients received 
carbapenems, 9.8% received aminoglycosides, and 5.9% received 
fluoroquinolones (The total number is more than 100%, since most 
of the patients received more than one antimicrobial agent). 
 
Table 2: Demographic and clinical features of patients with infections caused by carbapenem resistant Acinetobacter spp. (n = 51) 





 Pediatric patients 8 (15.7) 
 Adult patients 43 (84.3) 
Sex (male) 27 (52.9) 
Co-morbidity  
 Heart dysfunction 18 (35.3) 
 Malignancy 4 (7.8) 
 Diabetes Mellitus 18 (35.3) 
 Hyper tension 23 (45.1) 
 Chronic renal failure 8 (15.7) 
Admission to ICU 42 (82.4) 
Prior surgery 8 (15.7) 
Prior antibiotic use 50 (98) 
 BL/BLI 40 (78.4) 
 Carbapenem 24 (47.1)  
 Aminoglycosides 5 (9.8) 
 Fluoroquinolones 3 (5.9) 
Prior hospitalization 19 (37.3) 
Time to develop infection with CR-Ab(days) [median (range)] 7 (0 to 42) 
Duration of hospitalization (days) [median (range)] 27 (2 to 209) 
 Note: BL/BLI: β-lactam/β-lactamase inhibitor 
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The in-hospital mortality in this study of 51 patients was 49% 
(25/51). Eight patients died because of the reasons unrelated to 
infection and attributed mortality of the infection was found to be 
33.3% (17/51). Ten out of 17 patients who died had not received 
any effective therapy or received it for less than 48 h. Of these 10 
patients seven had bacteremia, one had pneumonia, one had wound 
infection and one had a urinary tract infection. These were not 
included in further analysis.  
Successful clinical outcome of the infection was observed in 32 out 
of 41 patients (78.0%). Seven out of nine patients whose infections 
were unresponsive to therapy died and two were discharged during 
illness. Table 3 presents the clinical response associated with the 
site of the infection and the type of treatment regimen followed. 
Colistin was most commonly used 78.0% (32/41 cases) either as 
monotherapy (4 cases) or combination therapy (28 cases) along 
with another antibacterial agent. 160 to 240 mg (2 to 3 MIU) of 
Colistimethate sodium (CMS) per 8 or 12 h was administered and 
doses were adjusted according to the renal functions. 
The PDR isolate of Acinetobacter baumannii was isolated from 
pleural effusion; the patient was successfully treated with Colistin, 
rifampin and sulbactam combination along with adjunctive 
procedure (drainage of pleural effusion). 
Particular attention was paid to the successful clinical outcome 
observed with carbapenem therapy. In all the cases patients were 
administered with 1 g dosing every 8 h with prolonged infusion over 
a period of 3 h. In all four cases patient had received antibiotics with 
an adjunctive procedure (eg. catheter removal, drainage, or 
debridement) for the removal of focus of infection. 
 
Table 3: Clinical response associated with the type of the infection and type of treatment regimen followed 










COL 4 4 (100) 2/2 (100) 2/2 (100) - - 
CAR 4 4 (100) 2/2 (100) - 2/2 (100) - 
Tg 1 1 (100) - - 1/1 (100) - 
Combination therapy 
COL+CAR 18 11 (61.1) 3/9 (33.3) 4/4 (100) 4/5 (80.0) - 
COL+non CAR combination 10 8 (80) 3/5 (60) 2/2 (100) 3/3 (100) - 
1. COL+Tg 7 5 (71.4) 2/4 (50) 1/1 (100) 2/2 (100)  
2. COL+Rif+sul 3 3 (100) 1/1 (100) 1/1 (100) 1/1 (100) 
Non COL combination 4 4 (100) 2/2 (100) - 1/1 (100) 1/1 (100) 
1. CAR+Tg+sul 1 1 (100) 1/1 (100) - - - 
2. CAR+TOB  1 1 (100) 1/1 (100) - - - 
3. CAR+Ak 1 1 (100) - - 1/1 (100) - 
4. COT+NF 1 1 (100) - - - 1/1 (100) 
Total 41 32 (76.2) 12/20 (60) 8/8 (100) 11/12 (91.7) 1/1 (100) 
Note: COL: Colistin, CAR: Carbapenem, Tg: Tigecyclin, Rif: Rifampin, sul: sulbactam, TOB: Tobramycin, Ak: Amikacin, NF: Nitrofurantoin. 
 
DISCUSSION 
The remarkable ability of Acinetobacter to upregulate or acquire 
resistance determinants makes it one of the organisms threatening 
the current antibiotic era. It is an opportunistic pathogen which 
commonly targets the critically ill patients [1]. Carbapenem 
resistance in this species is now observed increasingly worldwide, 
and constitutes a sentinel event for emerging antimicrobial 
resistance [2]. This is a cause of concern due to poor outcome 
associated with infection caused by CR-Ab and limited treatment 
option available [3]. Aim of the study was to characterize CR-Ab 
isolates in our institute. Maximum (41.1%) isolates were obtained 
from respiratory secretions. Similar studies have also reported 
respiratory tract infection as a predominant infection caused by A. 
baumannii [13, 14]. The susceptibility profile of isolates recovered 
during the present study underscores the extremely limited 
therapeutic choices available for treatment of patients infected with 
CR-Ab. Colistin had maximum in vitro activity, with 98% followed by 
tigecyclin retaining sensitivity against 57% isolates. Furthermore, 
with reported PDR isolate of Acinetobacter baumannii from the 
study cohort adds to the rapidly escalating reports worldwide, for 
which there is no active agent [15, 16]. 
With 98% positivity of MHT and 94.1% positivity in EDTA disk 
synergy test, carbapenemases especially MBLs was found to be 
major resistance factor along with AmpC carbapenemase 
production. Our study is in accordance with previous reports from 
India on the occurrence of multiple carbapenemase encoding genes 
in A. baumannii, of which blaOXA-23 like and blaVIM have been reported 
to be the most common type of carbapenemases contributing to 
carbapenem resistance in clinical isolates of A. baumannii [17, 19]. 
There are also reports of Acinetobacter harboring blaNDM
On studying the patient characteristics it was seen that 98% patients 
were exposed to antibiotics, indicating severity of underlying 
conditions and also problem of high antimicrobial consumption. 
With 78.4% of patients exposed to BL/BLI antibiotics and 47.1% of 
patients receiving carbapenems, the increasing prevalence of CR-Ab 
may be associated with previous exposure to BL/BLI and 
carbapenem as reported by Goel et al. [20]. With 82.4% patients 
admitted to ICU and other co-morbidities indicate the patients group 
in the present study to be critically ill, making it more vulnerable for 
an opportunistic pathogen like Acinetobacter [1, 2]. 
 gene along 
with multiple other carbapenemase genes as demonstrated in the 
present study [17, 19]. It is possible that the spread of NDM 
carbapenemase may occur rapidly, mostly through A. baumannii 
rather than Enterobacteriacae, since A. baumannii may become 
much more difficult to eradicate. Thus, with emergence of the 
clinical isolates in which multiple carbapenem resistance 
mechanism coexists, show a very broad spectrum antibiotic 
resistance profile and it may seriously limit treatment options. 
Colistin containing combinations were most often used, as it can be 
seen that only colistin showed the maximum in vitro activity against 
the isolates compared to other group of antibiotics. In terms of 
outcomes though less preferred, colistin monotherapy (100% 
successful outcome) was found to be non-inferior when compared 
with combination therapy (67.9% successful outcome). This 
supports the data from the small number of relevant human studies 
suggesting non-inferiority of colistin monotherapy compared with 
combination therapy [21]. However, in severe infections caused by 
CR-Ab, most clinicians had reservations about colistin mono-therapy 
as there are raised concerns regarding potential problem of 
heteroresistance among Gram negative bacterial population exposed 
to colistin alone. In that case combination therapy may be helpful in 
improving outcomes and preventing bacterial resistance [21]. The 
clinical success seen in case of carbapenem monotherapy may have 
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been due to the association of adjunctive therapy and prolonged 
infusion dosage regimen used. As prolonged infusion is known to 
improve pharmacokinetic/pharmacodynamics parameters and 
removal of focus of infection is been reported to be associated with 
patient survival [3, 22]. Thus the extent to which carbapenem 
therapy contributed to the outcome is difficult to ascertain. 
Tigecyclin can be used to treat tissue infection and respiratory tract 
infections considering excellent tissue penetration but given the low 
mean peak serum concentrations, its use in bacteremia caused by 
organisms with MIC value ≥1 µg/ml is warranted [23]. 
There have been in vitro studies that demonstrated synergy between 
colistin and carbapenem against high level CR-Ab isolates that do not 
produce MBLs or OXA-24 carbapenemases [24]. Whereas no marked 
synergy or borderline synergy of colistin in combination with 
carbapenem against CR-Ab isolates producing OXA-23 and MBLs 
carbapenemases was observed [24-26]. Colistin-rifampicin, colistin-
tigecyclin, and rifampicin-sulbactam have been reported to exhibit 
promising bactericidal activity even against OXA-23 producing 
highly CR-Ab isolates [24-26]. These finding demonstrate that in 
vitro activity of antibiotic combinations in CR-Ab may be strain 
dependent [24-26]. Hence, with the demonstrated high prevalence 
of blaOXA-23 and blaVIM
Although it may seem paradoxical at first sight, carbapenems have 
been commonly prescribed against CR-Ab, particularly as adjuvant 
drug in combination with another active agent [3, 27]. Preclinical 
studies have suggested synergistic effect with enhanced 
antibacterial activity against CR-Ab for carbapenem-sulbactam and 
carbapenem-aminoglycoside combination [3, 27-29]. Non colistin 
containing carbapenem combination strategy may be potentially 
useful against CR-Ab, but more clinical data are needed to routinely 
recommend such practice.  
 genes in our isolates may be responsible 
behind better outcome with colistin-non carbapenem combination 
compared to colistin-carbapenem combination therapy against our 
isolates. 
Despite the reported findings, our study has several limitations. 
First, the study is uncontrolled in nature so there is no comparison 
of outcomes, including mortality and cure of infection with the 
control group. Second, with varied combination of antibiotics used 
to treat the infection caused by CR-Ab, individual data for each type 
of infection and the treatment regimen followed for the same 
becomes too limited to comment on its statistical significance. Third, 
clinical isolates were not tested for the susceptibility to rifampicin 
and plain sulbactam. 
CONCLUSION 
CR-Ab was prevalent in our setup. Coexistence of multiple 
carbapenemase genes including blaNDM 
CONFLICT OF INTERESTS 
in clinical isolates of CR-Ab is a 
worrying trend and it underlines the need for a stringent infection 
control practices along with antimicrobial stewardship to curb these 
Acinetobacter. The optimal treatment of infection caused by CR-Ab is 
still a debatable topic. Present study demonstrated better outcome 
with colistin-non carbapenem combination compared to colistin-
carbapenem combination against Acineobacter baumannii with high 
level carbapenem resistance due to OXA-23 carbapenemases and 
MBLs. It is clear that resistance mechanism plays a crucial role in 
deciding the effectiveness of various antibacterial combinations [27]. 
Thus, the knowledge of prevalent resistant mechanism among CR-Ab 
in an institutional setup may guide clinicians in choosing a preemptive 
therapy for CR-Ab infections and warrants further investigation. 
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